NHS England to Offer New Non-Hormonal Drug for Menopausal Hot Flushes
In a significant development for women's health, the NHS in England is set to provide a groundbreaking non-hormonal drug to prevent hot flushes, a common symptom of menopause. This move follows authorisation by the National Institute for Health and Care Excellence (Nice), the UK's medicines watchdog, on Wednesday.
Addressing a Widespread Issue
Hot flushes, medically known as vasomotor symptoms, impact approximately 70% of women undergoing menopause. These sudden and intense sensations of heat can severely disrupt daily life, affecting sleep quality, exercise routines, work productivity, and overall wellbeing. Despite the prevalence of this condition, safe and effective treatment options have been limited for decades.
Expanding Treatment Options
The newly approved drug, Veoza (also called fezolinetant), offers a vital alternative for women who cannot or prefer not to use hormone replacement therapy (HRT). HRT, while highly effective, is unsuitable for many individuals, including those with a history of breast or ovarian cancer, blood clots, or untreated high blood pressure. Some women also experience side-effects from HRT or seek non-hormonal solutions.
Veoza, manufactured by Astellas Pharma, works by blocking specific nerve pathways in the brain that trigger hot flushes and night sweats. It is administered as a 45mg tablet taken once daily. According to Nice, this treatment is cost-effective and provides meaningful symptom relief, representing good value for taxpayers.
Expert Perspectives
Helen Knight, director of medicines evaluation at Nice, emphasised the profound impact of menopausal symptoms on quality of life. She stated, "For those unable to take HRT, options have historically been limited, and we have heard clearly from patients how difficult that can be. This decision will give much-needed relief to those for whom HRT is unsuitable."
Dr Sue Mann, national clinical director in women's health for NHS England, welcomed the news, highlighting that menopausal symptoms can affect every aspect of a woman's life. She said, "It's another vital treatment option, which could help hundreds of thousands of women experiencing menopause to better manage their symptoms and feel more in control of their health."
Eligibility and Impact
It is understood that around 500,000 women in England will be eligible to benefit from this new treatment. While HRT remains the first-line option for moderate to severe vasomotor symptoms due to its established benefits and varied formulations, fezolinetant addresses an urgent need for those excluded from hormonal therapies.
This initiative marks a step forward in enhancing healthcare support for menopausal women, offering hope and improved management of debilitating symptoms through innovative medical solutions.
